[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100513422":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":24,"centralContacts":28,"locations":33,"responsibleParty":64,"collaborators":66,"id":70,"slug":10,"hasResults":71,"nctId":72,"briefTitle":73,"officialTitle":74,"acronym":10,"eligibilityCriteria":75,"healthyVolunteers":71,"sex":76,"minAge":77,"maxAge":10,"enrollmentInfo":78,"targetDuration":10,"studyType":81,"phases":10,"briefSummary":82,"conditions":83,"keywords":10,"overallStatus":36,"whyStopped":10,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":96},{"fullName":5,"class":6},"The Cleveland Clinic","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Optimize mGDMT",null,"NICM patients referred for mGDMT optimization",[13],"Diagnostic Test: Cardiac magnetic resonance (CMR)",{"label":15,"type":10,"description":16,"interventionNames":17},"MitraClip and mGDMT","NICM patients who are fully medically optimized with significant FMR at the time of the baseline CMR and are referred for Mitraclip treatment",[13],[19],{"type":20,"name":21,"description":22,"armGroupLabels":23,"otherNames":10},"DIAGNOSTIC_TEST","Cardiac magnetic resonance (CMR)","Cardiac magnetic resonance (CMR) at 6 months. If referred to MitraClip, CMR will be performed at 6 months from the procedure.",[15,9],[25],{"name":26,"affiliation":5,"role":27},"Deborah Kwon, MD","PRINCIPAL_INVESTIGATOR",[29],{"name":26,"role":30,"phone":31,"phoneExt":10,"email":32},"CONTACT","216-444-8526","kwond@ccf.org",[34],{"facility":35,"status":36,"city":37,"state":38,"zip":39,"country":40,"cosmosGeoPoint":41,"geoPoint":46,"contacts":47},"Cleveland Clinic","RECRUITING","Cleveland","Ohio","44195","United States",{"type":42,"coordinates":43},"Point",[44,45],-81.69541,41.4995,{"lat":45,"lon":44},[48,49,52,54,56,58,60,62],{"name":26,"role":30,"phone":31,"phoneExt":10,"email":32},{"name":50,"role":51,"phone":10,"phoneExt":10,"email":10},"Samir Kapadia, MD","SUB_INVESTIGATOR",{"name":53,"role":51,"phone":10,"phoneExt":10,"email":10},"Wilson Tang, MD",{"name":55,"role":51,"phone":10,"phoneExt":10,"email":10},"David Chen, PhD",{"name":57,"role":51,"phone":10,"phoneExt":10,"email":10},"Xiaofeng Wang, PhD",{"name":59,"role":51,"phone":10,"phoneExt":10,"email":10},"Marc Gillinov, MD",{"name":61,"role":51,"phone":10,"phoneExt":10,"email":10},"Christopher Nguyen, PhD",{"name":63,"role":51,"phone":10,"phoneExt":10,"email":10},"Nancy Obuchowski, PhD",{"type":27,"investigatorFullName":26,"investigatorTitle":65,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Principal Investigator",[67],{"name":68,"class":69},"National Heart, Lung, and Blood Institute (NHLBI)","NIH","100513422",false,"NCT05965258","Phenotypic Classification of FMR With CMR","Improving Phenotypic Classification and Prediction of Treatment Outcomes in Patients With Non-ischemic Cardiomyopathy and Functional Mitral Regurgitation","Inclusion Criteria:\n\n1 CMR LVEF \\\u003C55% 2.FMR Fraction\\>20% or echo criteria consistent with at least moderate mitral regurgitation with adequate image quality\n\nExclusion Criteria:\n\n1. \\>moderate aortic regurgitation\u002Fstenosis,\n2. \\\u003C18 years of age,\n3. acute myocarditis,\n4. eGFR\\\u003C15\n5. HCM\n6. cardiac amyloidosis\u002Fsarcoidosis\n7. prior mitral valve intervention\n8. myocardial infarction within 8 weeks of CMR","ALL","18 Years",{"count":79,"type":80},360,"ESTIMATED","OBSERVATIONAL","The goal of the current research is to develop personalized risk prediction for functional mitral regurgitation (FMR) patients through explainable unsupervised phenomapping enriched with advanced cardiac magnetic resonance (CMR) imaging biomarkers, and to determine the CMR predictors of reverse remodeling following modern therapies for FMR.\n\nThe prospective study entails aiming to recruit 360 adult patients (ages \\>18 years) with EF 10-50% and FMR RF\\> 20%, who are clinically referred for CMR evaluation. Patients who enroll in our study will be referred for optimization of mGDMT and will undergo follow-up CMR studies at 6months. NICM patients who are fully medically optimized with significant FMR at the time of the baseline CMR and are referred for Mitraclip treatment will undergo follow-up CMR 6 months from Mitraclip intervention. NICM patients referred for mGDMT optimization, but have persistent or progressive FMR at the time of 6 month follow-up CMR and referred for Mitraclip therapy, will undergo a 2nd follow-up CMR 6 months from Mitraclip therapy.",[84,85,86],"Nonischemic Congestive Cardiomyopathy","Functional Mitral Regurgitation","Ischemic Cardiomyopathy","2025-10-17",{"date":89,"type":90},"2025-10-20","ACTUAL",{"date":92,"type":90},"2023-08-29",{"date":94,"type":80},"2028-12-31",{"name":5,"class":6},1]